> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Closer Drug Postapproval Monitoring Needed: Researchers
- URL: https://www.fdaweb.com/closer-drug-postapproval-monitoring-needed-researchers/
- Published: 2022-04-19T12:00:00.000Z
- Updated: 2026-09-14T17:41:15.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5151629

Harvard Medical School researchers say that study findings suggest that extrapolation by FDA beyond pivotal trial data to final indications is common, highlighting a need for closer postapproval monitoring. “Although extrapolations may be grounded in reasonable clinical predictions,” the researchers [write](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2791292?ref=fdaweb.com) in the *Journal of the American Medical Association*, they can limit the generalizability of such indications to specific prescribing decisions. These findings suggest a greater need for close postapproval monitoring to determine whether new safety issues arise, or effectiveness differs from expectations when these medications are used in broader real-world populations.”

The researchers conclude that when extrapolation is necessary at the time a drug is approved, its details should be made clear in the labeled indications for physicians and patients. “Until that time,” they say, “it would be useful for physicians to recognize that the FDA-approved indication alone may not be sufficient information on which to decide whether a given medication will benefit a patient who may differ meaningfully from those studied in the clinical trials on which approval was based.”